Genovefa D. Kolovou*, Gerald F. Watts, Dimitri P. Mikhailidis, Pablo Pérez-Martínez, Samia Mora, Helen Bilianou, George Panotopoulos, Niki Katsiki, Teik C. Ooi, José Lopez-Miranda, Anne Tybjærg-Hansen, Nicholas Tentolouris and Børge G. Nordestgaard Pages 515 - 537 ( 23 )
Postprandial hypertriglyceridaemia, defined as an increase in plasma triglyceride-containing lipoproteins following a fat meal, is a potential risk predictor of atherosclerotic cardiovascular disease and other chronic diseases. Several non-modifiable factors (genetics, age, sex and menopausal status) and lifestyle factors (diet, physical activity, smoking status, obesity, alcohol and medication use) may influence postprandial hypertriglyceridaemia. This narrative review considers the studies published over the last decade that evaluated postprandial hypertriglyceridaemia. Additionally, the genetic determinants of postprandial plasma triglyceride levels, the types of meals for studying postprandial triglyceride response, and underlying conditions (e.g. familial dyslipidaemias, diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver and chronic kidney disease) that are associated with postprandial hypertriglyceridaemia are reviewed; therapeutic aspects are also considered.
Postprandial hypertriglyceridaemia, triglycerides, atherosclerotic cardiovascular disease, oral fat tolerance test, familial dyslipidaemia, diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver, chronic kidney disease, statins, ezetimibe, nicotinic acid, fibrates, n-3 fatty acids, anti-obesity drugs, PCSK9 inhibitors, lipoprotein apheresis, bariatric surgery.
Cardiology Department and LDL-Apheresis Unit, Onassis Cardiac Surgery Center, Athens, Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Department of Clinical Biochemistry, Royal Free Hospital campus, University College London Medical School, University College London (UCL), London, Lipid and Atherosclerosis Unit, IMIBIC/Reina Sofia University Hospital/University of Cordoba, and CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Center for Lipid Metabolomics, Divisions of Preventive and Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, Department of Cardiology, Tzanio Hospital, Piraeus, Department of Obesity and Metabolism, Hygeia Hospital, Athens, First Department of Internal Medicine, Division of Endocrinology-Metabolism, Diabetes Center, AHEPA University Hospital, Thessaloniki, Department of Medicine, Division of Endocrinology and Metabolism, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Lipid and Atherosclerosis Unit, IMIBIC/Reina Sofia University Hospital/University of Cordoba, and CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen